Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study
Open accessThe DOI matches its Crossref record; 84 of the 86 references it cites were found in a registry or an index; 5 of the 21 sources its claims cite were checked for support.
Abstract
Several health-promoting effects of kefir have been suggested, however, there is limited evidence for its potential effect on gut microbiota in metabolic syndrome This study aimed to investigate the effects of regular kefir consumption on gut microbiota composition, and their relation with the components of metabolic syndrome. In a parallel-group, randomized, controlled clinical trial setting, patients with metabolic syndrome were randomized to receive 180 mL/day kefir (n = 12) or unfermented milk (n = 10) for 12 weeks. Anthropometrical measurements, blood samples, blood pressure measurements, and fecal samples were taken at the beginning and end of the study. Fasting insulin, HOMA-IR, TNF-α, IFN-γ, and systolic and diastolic blood pressure showed a significant decrease by the intervention of kefir (p ≤ 0.05, for each). However, no significant difference was obtained between the kefir and unfermented milk groups (p > 0.05 for each). Gut microbiota analysis showed that regular kefir consumption resulted in a significant increase only in the relative abundance of Actinobacteria (p = 0.023). No significant change in the relative abundance of Bacteroidetes, Proteobacteria or Verrucomicrobia by kefir consumption was obtained. Furthermore, the changes in the relative abundance of sub-phylum bacterial populations did not differ significantly between the groups (p > 0.05, for each). Kefir supplementation had favorable effects on some of the metabolic syndrome parameters, however, further investigation is needed to understand its effect on gut microbiota composition.
Overview
CoChat Summary
## TL;DR
This randomized controlled study tested 12 weeks of kefir (180 mL/day) versus unfermented milk in adults with metabolic syndrome and found some within-group improvements in insulin resistance, inflammatory markers, blood pressure, and gut microbiota, but no significant differences between groups for these outcomes. Kefir significantly increased only the relative abundance of Actinobacteria (p = 0.023), while overall diversity measures and most microbiota changes were not significant.
## Key findings
- A total of 22 participants completed the trial after randomization of 40 eligible participants; 12 received kefir and 10 received unfermented milk.
- After 12 weeks, kefir was associated with significant within-group decreases in fasting insulin and HOMA-IR (p = 0.050), TNF-α (p = 0.015), IFN-γ (p = 0.013), systolic BP (p = 0.041), and diastolic BP (p = 0.019), but these improvements were not significant versus the milk group.
- Gut microbiota analysis showed a significant increase only in Actinobacteria with kefir (p = 0.023); no significant change was observed for Bacteroidetes, Proteobacteria, or Verrucomicrobia.
- No significant differences were found between groups in alpha/beta diversity metrics, OTU counts, Firmicutes/Bacteroidetes ratio, or changes in sub-phylum taxa; no side effects were reported.
## Methods
- Parallel-group, randomized, controlled clinical trial in adults aged 18–65 years with metabolic syndrome, recruited from Ege University outpatient clinic; trial ran from March 2015 to July 2017 and was registered as NCT03966846.
- Participants were randomized to kefir (180 mL/day, n = 12) or unfermented milk (180 mL/day, n = 10) for 12 weeks; diets and physical activity were intended to remain habitual.
- Outcomes included 24-h dietary recalls, anthropometry, fasting blood biomarkers, blood pressure, fecal 16S rRNA sequencing of the V3-V4 region, and statistical comparisons/correlations using tests including Kruskal–Wallis, Mann–Whitney U, Spearman, and PERMANOVA.
## Limitations
- The paper states that it examined only microbiota composition, not microbiota functionality; it says that metabolite-based markers could have improved interpretation and calls this the main limitation.
- The paper states that the small number of participants in each arm is another limitation.
- Evident from the text: despite randomization, the final sample was small (22 completers), which limits precision and makes between-group comparisons underpowered.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Principal coordinate analysis (PCoA) plot of the unweighted (A) and weighted (B) UniFrac distance matrices in the study groups. The plots were generated using EMPeror [36]. Axis titles indicate the percentage variations. The colors indicate sampling time (red: week 0, blue: week 12).](https://figures.cochat.ai/paper-figures/8c30915e06de4ec8baf794ccba189570/effects-of-regular-kefir-consumption-on-gut-microbiota-in-patients-with-figure-5.jpg)
Verification
Claims the paper makes
4 Valid · 0 Not valid · 6 Not checked · 75 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Primary, the low-grade chronic inflammation state in MetS has been explained by the metabolic endotoxemia that was a result of gut dysbiosis [6,7].”
§ Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study > 1. Introduction
What the sources say
- Supportedcites [6] Burcelin, 2009, The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?, Front Biosci source
Section 2.4 (p. n/a) states that a fat-enriched diet dramatically changes the gut microflora and that 'the molecular mechanisms linked to the change in microflora was related to the release into the blood of an extract from Gram negative bacteria: lipopolysaccharides (LPS)', which 'can trigger a metabolic inflammatory state' leading to insulin resistance and obesity. Section 4.4 makes the same causal chain explicit (intestinal microflora regulates the inflammatory tone; endotoxemia 2-3 fold correlated with inflammation; linked to a 100-fold reduction of Bifidobacteria), and Section 5.1 extends it to metabolic syndrome in humans ('the origin of the endotoxemia is related to the intestinal microflora ... controlling the intestinal flora and enteric LPS permeability would be a key target for the control of the onset of inflammation-induced metabolic diseases'; 'A growing body of evidence supports the influence of the endotoxin pathway in metabolic syndrome'). The citing sentence's chain — gut dysbiosis → metabolic endotoxemia → low-grade inflammation in MetS — is thus the paper's own account, though the underlying experimental data are the author's mouse/human studies (refs 20, 22, 54) rather than a MetS trial. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [7] Cani, 2007, Metabolic endotoxemia initiates obesity and insulin resistance, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the effects of probiotic and prebiotic supplementation on metabolic health have been examined in previous studies, the results are inconsistent due to the choice of probiotic strain, formulation of the probiotic, outcome of interest, and duration of the intervention [12,13,14].”
§ Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study > 1. Introduction
What the sources say
- Partly supportedcites [12] Festi, 2014, Gut microbiota and metabolic syndrome, World J. Gastroenterol. sourceExperimental — accuracy not yet measured
Our copy does support the 'inconsistent results' half of the claim: the Prebiotics section (p. 10) reports that a meta-analysis found significant reductions in post-prandial glucose and insulin while 'data regarding effects on body weight, total energy intake, satiety, GLP-1 and peptide YY production and inflammatory pattern seem to be controversial', and the Probiotics section (p. 9) states that despite promising results the evidence for probiotics in obesity 'are still weak' and their therapeutic use 'has not yet been recommended'; the CONCLUSION (p. 10) repeats that solid clinical evidence has not emerged. However, the paper nowhere attributes this inconsistency to the specific reasons the citing sentence gives — choice of probiotic strain, formulation of the probiotic, outcome of interest, and duration of intervention; its tables merely list heterogeneous strains, doses and durations without offering them as the explanation. That explanatory part of the claim is not in our copy. (LLM, conf=0.72)
- Partly supportedcites [13] Anhe, 2015, Probiotics as Complementary Treatment for Metabolic Disorders, Diabetes Metab. J. sourceExperimental — accuracy not yet measured
The Conclusions report inconclusive probiotic results and attribute difficulty comparing studies to differences in protocols, including treatment duration. The paper also discusses strain-specific effects, product formulations, and differing metabolic outcomes. Its discussion of prebiotics does not establish that prebiotic supplementation has similarly inconsistent results for these reasons. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [14] Cani, 2015, Novel opportunities for next–generation probiotics targeting metabolic syndrome, Curr. Opin. Biotechnol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Most of the animal and human studies have reported that obesity and insulin resistance are associated with an altered ratio of Firmicutes and Bacteroidetes [8,9].”
§ Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study > 1. Introduction
What the sources say
- Partly supportedcites [8] Ley, 2005, Obesity alters gut microbial ecology, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results and Discussion report that obese ob/ob mice had fewer Bacteroidetes and more Firmicutes than lean mice. This supports the obesity–altered-ratio association in one animal study, but the paper does not establish what most animal and human studies report or link the ratio to insulin resistance; it says the obesity finding deserves exploration in humans. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [9] Backhed, 2005, Host–bacterial mutualism in the human intestine, Science source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In particular, insulin and HOMA–IR levels were significantly decreased, and also pro–inflammatory cytokines (TNF–α and IFN–γ) and blood pressure were ameliorated by kefir consumption.”
§ Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study > 4. Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the unfermented milk group, the phyla Bacteroidetes (66%), Firmicutes (27%), Verrucomicrobia (0.01%), Actinobacteria (0.01%), and Proteobacteria (0.03%) were detected at the baseline, however, the relative abundance of these phyla were changed to 33%, 56%, 0.03%, 0.04%, and 0.02% respectively after the intervention (Figure 2).”
§ Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study > 3. Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
41 more claims
Create a free account to see all 85 claims and to verify the 4 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 14
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kefir consumption does not seem to result in negative effects (18) for adult humans (19) or animals (20).”
From Kefir and Intestinal Microbiota Modulation: Implications in Human Health (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This intestinal modulation interferes with metabolic parameters, characteristic of metabolic syndrome, showing improvement in fasting insulin and insulin resistance index (HOMA-IR), and a decrease in pro-inflammatory cytokines, such as TNF-α and interferon-gama (IFN-γ), and in systolic and diastolic pressure.”
From Kefir and Intestinal Microbiota Modulation: Implications in Human Health (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“body weight gain and BMI were positively correlated with the relative abundance of Firmicutes and Proteobacteria and negatively correlated with the relative abundance of Clostridia.”
From Kefir and Intestinal Microbiota Modulation: Implications in Human Health (2021) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“In humans, modulation of intestinal microbiota also occurs after the consumption of kefir, as discussed by Bellikci-Koyu et al. (19) who investigated individuals with metabolic syndrome that were supplemented with kefir for 12 weeks (Table 1). After the intervention, there was a significant increase in Actinobacteria, as well as changes in the genera of the phyla Bacteriodetes and Firmicutes, in”
From Kefir and Intestinal Microbiota Modulation: Implications in Human Health (2021) · cites this paper as [19]
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698 · cited 1×
“For this purpose, raw data were imported into QIIME2 [31], filtered and controlled for quality and chimeric sequences using DADA2, q2-demux, and dblur scripts [32,33].”
MethodReproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 1×
“showed the linked between gut microbiota and obesity, there has been growing evidence that suggests a causal relationship between gut microbiota and the components of MetS [5].”
BackgroundKlindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., & Glöckner, F. O. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks808 · Cited by 8,850 · cited 1×
“The 16S rRNA sequences were amplified using previously-described primers targeting the V3-V4 region, frequently used to study bacterial diversity [27], with Illumina adapter overhang sequences added, as directed by the manufacturer.”
MethodHuman gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“Our results supported the previous reports, which revealed increased Firmicutes and decreased the abundance of Bacteroidetes are associated with obesity [64].”
ResultA core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823 · cited 1×
“revealed a higher proportion of Actinobacteria in obese individuals compared to lean individuals [65].”
BackgroundChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Research works printed but not linked: 1
- Koyu, 2018, A functional food: Kefir, J. Nutr. Diet., 46, 166
Cited by
Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration
Leeming, E. R., Johnson, A. J., Spector, T. D., & Le Roy, C. I. (2019) · Nutrients · doi:10.3390/nu11122862 · Cited by 817
“Bellikci-koyu [71] 2019 Humans 22 Randomised parallel, controlled trial 24-h food recall × 2 (week 0, week 12) Two treatment groups: (1) 180 mL/day kefir (12); (2) unfermented milk (10) control 12 weeks 2× samples: baseline, end of intervention No Kefir was associated with a significant increase in the relative abunda…”
MethodKefir and Its Biological Activities
Azizi, N. F., Kumar, M. R., Yeap, S. K., Abdullah, J. O., Khalid, M., Omar, A. R., Osman, M. A., Mortadza, S. A. S., & Alitheen, N. B. (2021) · Foods · doi:10.3390/foods10061210 · Cited by 256
“A randomized trial in twelve subjects with metabolic syndrome whose diets were supplemented with 180 mL/day kefir showed the modulation of intestinal microbiota, with a significant rise in Actinobacteria, as well as variations in the genera of the phyla Bacteriodetes and Firmicutes [181].”
BackgroundThe Development and Evaluation of a Literature-Based Dietary Index for Gut Microbiota
Kase, B. E., Liese, A. D., Zhang, J., Murphy, E. A., Zhao, L., & Steck, S. E. (2024) · Nutrients · doi:10.3390/nu16071045 · Cited by 221
“Kefir and fermented dairy intake were associated with beneficial changes in gut microbiota, mainly an increase in actinobacteria [30].”
BackgroundEating Fermented: Health Benefits of LAB-Fermented Foods
Castellone, V., Bancalari, E., Rubert, J., Gatti, M., Neviani, E., & Bottari, B. (2021) · Foods · doi:10.3390/foods10112639 · Cited by 178
Guzel-Seydim, Z. B., Gökırmaklı, Ç., & Greene, A. K. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.04.041 · Cited by 172
Metadata
- Authors
- BELLIKCI-KOYU, E., SARER-YUREKLI, B. P., AKYON, Y., AYDIN-KOSE, F., KARAGOZLU, C., OZGEN, A. G., BRINKMANN, A., NITSCHE, A., ERGUNAY, K., YILMAZ, E., & BUYUKTUNCER, Z.
- Affiliations
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Hacettepe University, Ankara 06230, Turkey
- Ege University (TR)
- Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey
- Department of Biochemistry, Faculty of Pharmacy, Ege University, Izmir 35040, Turkey
- Department of Dairy Technology, Faculty of Agriculture, Ege University, Izmir 35040, Turkey
- Department of Endocrinology, Faculty of Medicine, Ege University, Izmir 35040, Turkey
- Robert Koch Institute (DE)
- Department of Medical Biology, Acıbadem Mehmet Ali Aydınlar University, Istanbul 34752, Turkey
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2019-09-04
- Volume
- 11
- Issue
- 9
- Pages
- 2089
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC6769690
- OpenAlex
- W2971933675
- Cited by
- 144
- References
- 86
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 24 · 2023: 25 · 2022: 21 · 2021: 22 · 2020: 14 · 2019: 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Acibadem University Open Access Repository (submittedVersion)
- Publication server of the Robert Koch Institute (Robert Kock Institute) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, cc-by)
- Funders
- Turkish Council of Higher Education (XX)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Nursing › Nutrition and Dietetics › Infant Nutrition and Health
- Keywords
- kefir, gut microbiota, metabolic syndrome, fermented milk, insulin resistance, fasting insulin, HOMA-IR, blood pressure, TNF-α, interferon-gamma, actinobacteria, Bacteroidetes, Proteobacteria, Verrucomicrobia, probiotics
- MeSH terms
- Gastrointestinal Microbiome, Kefir, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Female, Humans, Lipids, Male, Middle Aged, Phylogeny, Metabolic Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study. https://app.cochat.ai/papers/10.3390/nu11092089
- The paper
- BELLIKCI-KOYU, E., SARER-YUREKLI, B. P., AKYON, Y., AYDIN-KOSE, F., KARAGOZLU, C., OZGEN, A. G., BRINKMANN, A., NITSCHE, A., ERGUNAY, K., YILMAZ, E., & BUYUKTUNCER, Z. (2019). Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study. Nutrients. https://doi.org/10.3390/nu11092089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.